Cover Image
市場調查報告書

呼吸道合胞病毒(RSV)融合蛋白(RSV-F 蛋白):開發中產品分析

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 364865
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
呼吸道合胞病毒(RSV)融合蛋白(RSV-F 蛋白):開發中產品分析 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 132 Pages
簡介

本報告提供以呼吸道合胞病毒(RSV)融合蛋白(RSV-F 把蛋白)為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

呼吸道合胞病毒(RSV)融合蛋白(RSV-F 蛋白)概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Ablynx NV
  • Agilvax, Inc.
  • Aridis Pharmaceuticals LLC
  • Bavarian Nordic A/S
  • Celltrion, Inc.
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gene Techno Science Co., Ltd.
  • GenVec, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • iBio, Inc.
  • Johnson & Johnson
  • mAbxience S.A.
  • MedImmune, LLC
  • Medivir AB
  • Mucosis B.V.
  • Navigen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • 武田藥品工業
  • The International Biotechnology Center (IBC) Generium
  • Vaxart, Inc.
  • VLP Biotech, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0659TDB

Summary

Global Markets Direct's, 'Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016', provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
  • The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Overview
  • Therapeutics Development
    • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Stage of Development
    • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Therapy Area
    • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Indication
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Companies
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Universities/Institutes
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Agilvax Inc
    • Aridis Pharmaceuticals LLC
    • Aviragen Therapeutics Inc
    • Bavarian Nordic A/S
    • Celltrion, Inc.
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gene Techno Science Co., Ltd.
    • GenVec, Inc.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • iBio, Inc.
    • Johnson & Johnson
    • mAbxience S.A.
    • MedImmune LLC
    • Medivir AB
    • Mucosis B.V.
    • Navigen Pharmaceuticals, Inc.
    • NeuClone Pty Ltd
    • Novavax, Inc.
    • Regeneron Pharmaceuticals Inc
    • Takeda Pharmaceutical Company Limited
    • TechnoVax, Inc.
    • The International Biotechnology Center (IBC) Generium
    • Vaxart Inc
    • VBI Vaccines Inc
    • VLP Biotech, Inc.
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drug Profiles
    • (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AK-0529 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALX-0171 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AX-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTA-585 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-32T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DT-preF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNR-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GV-2311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-61187165AAA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-61187191AAA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-64400141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-8897 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MVA-RSV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palivizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • presatovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus (virus like particle) vaccines - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RV-521 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suptavumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SynGEM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Dormant Projects
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Discontinued Products
  • Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Featured News & Press Releases
    • Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus
    • Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
    • Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium
    • Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults
    • Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults
    • Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
    • Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
    • Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine
    • Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine
    • Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program
    • May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
    • May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults
    • May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
    • May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalized with a RSV infection
    • Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Ablynx NV, H2 2016
  • Pipeline by Agilvax Inc, H2 2016
  • Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Pipeline by Aviragen Therapeutics Inc, H2 2016
  • Pipeline by Bavarian Nordic A/S, H2 2016
  • Pipeline by Celltrion, Inc., H2 2016
  • Pipeline by Emergent BioSolutions Inc., H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Pipeline by GenVec, Inc., H2 2016
  • Pipeline by Gilead Sciences, Inc., H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by iBio, Inc., H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by mAbxience S.A., H2 2016
  • Pipeline by MedImmune LLC, H2 2016
  • Pipeline by Medivir AB, H2 2016
  • Pipeline by Mucosis B.V., H2 2016
  • Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Pipeline by NeuClone Pty Ltd, H2 2016
  • Pipeline by Novavax, Inc., H2 2016
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Pipeline by TechnoVax, Inc., H2 2016
  • Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Pipeline by Vaxart Inc, H2 2016
  • Pipeline by VBI Vaccines Inc, H2 2016
  • Pipeline by VLP Biotech, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top